The Global Health Innovative Technology Fund (GHIT Fund) has announced today that it will invest in innovative malaria eradication tools, a new diagnostic test for tuberculosis, and new treatments for cutaneous leishmaniasis and soil-transmitted helminthiasis infections.
GHIT awarded US$687,715 to a partnership between GeneDesign, Inc., a Japan-based biotech, and DNDi to develop a better treatment for cutaneous leishmaniasis. With GHIT’s investment, GeneDesign and DNDi will assess an immunomodulator with an anti-parasitic drug to enhance healing and parasite clearance of skin lesions. This proposed approach shows potential to work faster than current drugs, reduce scarring, and prevent relapse.
Photo credit: Fabio Nascimento-DNDi